New Retina Radio is a place to hear stories about retina that are told nowhere else.
View full description +
Subscribe
09.10.26
Spotlight on UNITY® VCS: Breaking New GroundJay Sridhar, MD; and Nina Berrocal, MD
In this episode of RetinaLive focused on UNITY® VCS|CS, Jay Sridhar, MD is joined by Nina Berrocal, MD for a forward-looking discussion on adopting next-generation surgical technology. The conversation explores how UNITY® VCS is enabling innovation in a new retina practice setting, with a focus on fluidics stability, integrated anterior and posterior segment capabilities, and enhanced intraoperative efficiency. Through real-world perspectives, the episode highlights the role of advanced technology in simplifying surgical workflows, and supporting the training of the next generation of retina surgeons.
For Important Product Information, visit unityvcs.com.
Speakers are paid Alcon consultants. The views expressed are their own.
Disclaimers:
4:05: Based on Bench Data. UNITY® VCS with HYPERVIT® 30k cpm vitrectomy probe vs. CONSTELLATION® VS with HYPERVIT® 20k cpm vitrectomy probe
6:13: *Mean fluctuation at flow vs. setpoint of 2.36 ± 2.13, 4.19 ± 1.97, 1.84 ± 2.82, and 2.13 ± 2.86 mmHg during phacoemulsification, irrigation/aspiration (IA), vitrectomy, and extrusion/fragmentation, respectively. IOP setpoint as low as 16 mmHg (posterior) and 20 mmHg (anterior) without exceeding a mean fluctuation of 4.19 ± 1.97 mmHg
9:08: MSLP(4) is 3 times faster than SSLP
References:
1. UNITY™ VCS and CS User Manual Unity Phaco Handpiece Directions for Use.
2. Alcon data on file 2024 (REF-24615)
3. Alcon data on file 2024 (REF-24379)
4. Alcon data on file 2024 (REF-24576)
5. Alcon Data on File (REF-27800)
6. UNITY™ VCS and CS User Manual
7. Alcon data on file 2024. (REF-24899)
Sponsored by Alcon, Inc. © 2026 Alcon Inc. 07/26 US-UVC-2600112
Sponsored by Alcon
Play Episode08.27.26
ASRS '26: ArMaDa/GARDian Results and Real-World YAG Complication IncidenceJay Chhablani, MD; and Jordan Deaner, MD
Editorially Independent Content Supported by Genentech
08.20.26
Comparing Ocular AEs in Next-Gen TreatmentsKatherine Talcott, MD; Akshay Thomas, MD; and Nita Valikodath, MD, MS
Editorially Independent Content Supported by Genentech
08.18.26
The Story Behind LYTENAVA™: From FDA Approval to Retina PracticeBarry Kuppermann, MD, PhD; and Bob Jahr, CEO of Outlook Therapeutics
Sponsored by Outlook Therapeutics
08.12.26
The Fellow Eye: Episode 6Justin C. Muste, MD; David Fell, MD; Monia Reding, MD; and Benjamin Young, MD
Editorially Independent
08.05.26
ASRS '26: SOL-1 and TRUCKEE at 4.5 YearsDilsher Dhoot, MD; and Carl Danzig, MD
Editorially independent content, supported by Genentech.
07.16.26
New Retina Radio Journal Club w/ VBS: Clinical Features and Outcomes of IOFB RemovalJordan Deaner, MD; Vaidehi Dedania, MD; and Rehan Hussain, MD
Editorially Independent Content Supported by Genentech
07.08.26
Barriers to Care, Patient Education, and Treatment Decisions in Geographic AtrophyGeeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD
Editorially independent content, supported by Astellas & Zeiss
07.08.26
Evolving Practice Patterns and Dosing Strategies in Geographic AtrophyGeeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD
Editorially independent content, supported by Astellas & Zeiss
Show More